Shopping Cart
Remove All
Your shopping cart is currently empty
Ontorpacept
😃Good
Catalog No. T81605Cas No. 2131089-46-6
Alias TTI-621
Ontorpacept (TTI-621) is a soluble fusion protein comprising the N-terminal (1-118) of human SIRPα fused to the Fc region of human IgG1. This N-terminal (1-118) segment serves as the binding domain for CD47, an inhibitor of macrophage-mediated phagocytosis. As a checkpoint inhibitor that blocks CD47, ontorpacept exhibits antitumor activity [1].
Ontorpacept
Ontorpacept
😃Good
Catalog No. T81605Alias TTI-621Cas No. 2131089-46-6
Ontorpacept (TTI-621) is a soluble fusion protein comprising the N-terminal (1-118) of human SIRPα fused to the Fc region of human IgG1. This N-terminal (1-118) segment serves as the binding domain for CD47, an inhibitor of macrophage-mediated phagocytosis. As a checkpoint inhibitor that blocks CD47, ontorpacept exhibits antitumor activity [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Backorder | Backorder | |
| 5 mg | Inquiry | Backorder | Backorder |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Chemical Properties
| Description | Ontorpacept (TTI-621) is a soluble fusion protein comprising the N-terminal (1-118) of human SIRPα fused to the Fc region of human IgG1. This N-terminal (1-118) segment serves as the binding domain for CD47, an inhibitor of macrophage-mediated phagocytosis. As a checkpoint inhibitor that blocks CD47, ontorpacept exhibits antitumor activity [1]. |
| In vitro | Ontorpacept, at concentrations ranging from 0.001 to 1000 nmol/L administered over 2 hours, dose-dependently enhances macrophage phagocytosis of tumor cells in samples from patients with acute myeloid leukemia, myelodysplastic syndromes, multiple myeloma, B-cell acute lymphoblastic leukemia, and T-cell acute lymphoblastic leukemia, with an average EC50 of 10 nmol/L [1]. |
| In vivo | Ontorpacept, at a dose of 8 mg/kg administered intraperitoneally thrice weekly for four weeks, demonstrated antitumor activity in an acute myeloid leukemia xenograft model in SCID mice [1]. |
| Synonyms | TTI-621 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | ＜ 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 2131089-46-6 |
Storage & Solubility Information
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Ontorpacept | purchase Ontorpacept | Ontorpacept cost | order Ontorpacept | Ontorpacept in vivo | Ontorpacept in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.